Top

Journal of Cardiovascular Translational Research

Published in:

01-03-2014

Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling

Authors: Shweta R. Motiwala, Jackie Szymonifka, Arianna Belcher, Rory B. Weiner, Aaron L. Baggish, Hanna K. Gaggin, Anju Bhardwaj, James L. Januzzi Jr.

Published in: Journal of Cardiovascular Translational Research | Issue 2/2014

Abstract

Myocardial remodeling is pivotal in the progression and complication of chronic heart failure (HF). We assessed serial measurement of five biomarkers with biologic links to remodeling (biglycan, secreted frizzled-related protein 3, endostatin, insulin-like growth factor binding protein 7 [IGFBP7], mimecan) in 142 patients with HF followed through 882 office visits. IGFBP7 and mimecan were most associated with events; in fully adjusted models, lower IGFBP7 concentrations across visits independently predicted fewer events (odds ratio [OR] = 0.83; 95 % confidence interval [CI] = 0.73–0.95, p = 0.01). Subjects with rising mimecan had greater decrease in left ventricular end diastolic (p = 0.07) and systolic (p = 0.01) volumes, greater increase in ejection fraction (p = 0.02), and had lowest event rates. Statistical models suggested several HF medications might lead to changes in both IGFBP7 and mimecan values. The results suggest serial measurement of IGFBP7 provides prognostic information, while changes in mimecan provide unique information regarding myocardial remodeling.

Available only for authorised users

Chen, A. A., Wood, M. J., Krauser, D. G., Baggish, A. L., Tung, R., Anwaruddin, S., Picard, M. H., & Januzzi, J. L. (2006). NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J, 27(7), 839–845.PubMedCrossRef

Januzzi, J. L., Jr., Sakhuja, R., O'Donoghue, M., Baggish, A. L., Anwaruddin, S., Chae, C. U., Cameron, R., Krauser, D. G., Tung, R., Camargo, C. A., Jr., & Lloyd-Jones, D. M. (2006). Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med, 166(3), 315–320.PubMedCrossRef

Januzzi, J. L., Jr., Rehman, S., Mohammed, A. A., Bhardwaj, A., Barajas, L., Barajas, J., Kim, H.-N., Baggish, A. L., Weiner, R. B., Chen, A. A., Marshall, J. E., Moore, S. A., Carlson, W. D., Lewis, G. D., Shin, J., Sullivan, D., Parks, K., Wang, T. J., Gregory, S., Uthamalingam, S., & Semigran, M. J. (2011). Use of amino-terminal Pro-B type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol, 58, 1881–1889.PubMedCrossRef

Baggish, A. L., van Kimmenade, R. R., & Januzzi, J. L., Jr. (2008). The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am J Cardiol, 101(3A), 43–48.PubMedCrossRef

Mann, D. L., Barger, P. M., & Burkhoff, D. (2012). Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol, 60(24), 2465–2472.PubMedCentralPubMedCrossRef

Weiner, R. B., Baggish, A. L., Chen-Tournoux, A., Marshall, J. E., Gaggin, H. K., Bhardwaj, A., Mohammed, A. A., Rehman, S. U., Barajas, L., Barajas, J., Gregory, S. A., Moore, S. A., Semigran, M. J., & Januzzi, J. L., Jr. (2013). Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. European journal of heart failure, 15(3), 342–351.PubMedCrossRef

Chugh, S., Ouzounian, M., Lu, Z., Mohamed, S., Li, W., Bousette, N., Liu, P. P., & Gramolini, A. O. (2013). Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics, 13(15), 2324–2334.PubMedCrossRef

Bhardwaj, A., Rehman, S. U., Mohammed, A., Baggish, A. L., Moore, S. A., & Januzzi, J. L., Jr. (2010). Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. American heart journal, 159(4), 532–538. e531.PubMedCrossRef

Ahmed, M. S., Oie, E., Vinge, L. E., Yndestad, A., Andersen, G. G., Andersson, Y., Attramadal, T., & Attramadal, H. (2003). Induction of myocardial biglycan in heart failure in rats—an extracellular matrix component targeted by AT(1) receptor antagonism. Cardiovascular research, 60(3), 557–568.PubMedCrossRef

10.

Askevold, E. T., Aukrust, P., Nymo, S., Aakhus, S., Ranheim, T., Fiane, A., Dahl, C. P., Finsen, A. V., Yndestad, A., Gullestad, L., Latini, R., Masson, S., Tavazzi, L., & Ueland, T. (2012). GISSI-HF Investigators. Abstract 18191: secreted frizzled related protein 3, an inhibitor of Wnt-signaling, is upregulated in clinical and experimental heart failure. Circulation, 126(21 Supplement), A18191.

11.

Isobe, K., Kuba, K., Maejima, Y., Suzuki, J., Kubota, S., & Isobe, M. (2010). Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circulation journal : official journal of the Japanese Circulation Society, 74(1), 109–119.CrossRef

12.

Gramolini, A. O., Kislinger, T., Alikhani-Koopaei, R., Fong, V., Thompson, N. J., Isserlin, R., Sharma, P., Oudit, G. Y., Trivieri, M. G., Fagan, A., Kannan, A., Higgins, D. G., Huedig, H., Hess, G., Arab, S., Seidman, J. G., Seidman, C. E., Frey, B., Perry, M., Backx, P. H., Liu, P. P., MacLennan, D. H., & Emili, A. (2008). Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Molecular & cellular proteomics : MCP, 7(3), 519–533.CrossRef

13.

Dinh, W, Coll Barroso, M, Futh, R, Lankisch, M, Klein, R, Gulker, J, Bufe, A, Scheffold, T, Nickl, N, Seyfarth, M. 92012) Abstract P1288: Serum insulin like growth factor-i and its binding protein-7: novel promising biomarker in heart failure with preserved ejection fraction. Clinical Research in Cardiology; 101(Supplement 1).

14.

Petretto, E., Sarwar, R., Grieve, I., Lu, H., Kumaran, M. K., Muckett, P. J., Mangion, J., Schroen, B., Benson, M., Punjabi, P. P., Prasad, S. K., Pennell, D. J., Kiesewetter, C., Tasheva, E. S., Corpuz, L. M., Webb, M. D., Conrad, G. W., Kurtz, T. W., Kren, V., Fischer, J., Hubner, N., Pinto, Y. M., Pravenec, M., Aitman, T. J., & Cook, S. A. (2008). Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet, 40(5), 546–552.PubMedCentralPubMedCrossRef

15.

Voss, S, Nef, H, Szardien, S, Troidl, C, Kojonazarov, B, Visser, D, Hoffmann, J, Willmer, M, Hamm, C. W, Moellmann, H. 92012) Abstract 2014: Osteoglycin deficiency leads to maladaptive remodeling and severe cardiac dysfunction in a mouse model of cardiac hypertrophy. Eur Heart J; 33(Supplement 1):342.

16.

Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J., Solomon, S., & Spencer, K. T. (2006). St John Sutton M. Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr, 7(2), 79–108.PubMedCrossRef

17.

Brandan, E., Cabello-Verrugio, C., & Vial, C. (2008). Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol, 27(8), 700–708.PubMedCrossRef

18.

Fadic, R., Mezzano, V., Alvarez, K., Cabrera, D., Holmgren, J., & Brandan, E. (2006). Increase in decorin and biglycan in Duchenne Muscular Dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease. J Cell Mol Med, 10(3), 758–769.PubMedCrossRef

19.

Hoang, B., Moos, M., Jr., Vukicevic, S., & Luyten, F. P. (1996). Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem, 271(42), 26131–26137.PubMedCrossRef

20.

Svensson, A., Norrby, M., Libelius, R., & Tagerud, S. (2008). Secreted frizzled related protein 1 (Sfrp1) and Wnt signaling in innervated and denervated skeletal muscle. J Mol Histol, 39(3), 329–337.PubMedCrossRef

21.

Tufan, A. C., Daumer, K. M., & Tuan, R. S. (2002). Frizzled-7 and limb mesenchymal chondrogenesis: effect of misexpression and involvement of N-cadherin. Dev Dyn, 223(2), 241–253.PubMedCrossRef

22.

Glenjen, N., Mosevoll, K. A., & Bruserud, O. (2002). Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer, 101(1), 86–94.PubMedCrossRef

23.

Miyashita, M., Tajiri, T., Yanagi, K., Shimizu, T., Futami, R., Sasajima, K., & Tokunaga, A. (2003). Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors. Hepatogastroenterology, 50(50), 308–309.PubMed

24.

Gu, X. S., Lei, J. P., Shi, J. B., Lian, W. L., Yang, X., Zheng, X., & Qin, Y. W. (2011). Mimecan is involved in aortic hypertrophy induced by sinoaortic denervation in rats. Mol Cell Biochem, 352(1–2), 309–316.PubMedCrossRef

25.

Jazbutyte, V., Fiedler, J., Kneitz, S., Galuppo, P., Just, A., Holzmann, A., Bauersachs, J., & Thum, T. (2012). MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr), 35(3), 747–762.CrossRef

26.

Cavallari, L. H., & Limdi, N. A. (2009). Warfarin pharmacogenomics. Curr Opin Mol Ther, 11(3), 243–251.PubMed

27.

Grzymala-Lubanski, B., Sjalander, S., Renlund, H., Svensson, P. J., & Sjalander, A. (2013). Computer aided warfarin dosing in the Swedish national quality registry AuriculA — algorithmic suggestions are performing better than manually changed doses. Thromb Res, 131(2), 130–134.PubMedCrossRef

28.

Motiwala, S. R., Szymonifka, J., Belcher, A., Weiner, R. B., Baggish, A. L., Sluss, P., Gaggin, H. K., Bhardwaj, A., & Januzzi, J. L. (2013). Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail, 15(10), 1157–1163.PubMedCrossRef

29.

van Kimmenade, R. R., & Januzzi, J. L., Jr. (2012). Emerging biomarkers in heart failure. Clin Chem, 58(1), 127–138.PubMedCrossRef

30.

Januzzi, J. L., Jr. (2013). Natriuretic peptides as biomarkers in heart failure. J Investig Med, 61(6), 950–955.PubMed

Title: Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling
Authors: Shweta R. Motiwala
Jackie Szymonifka
Arianna Belcher
Rory B. Weiner
Aaron L. Baggish
Hanna K. Gaggin
Anju Bhardwaj
James L. Januzzi Jr.
Publication date: 01-03-2014
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 2/2014
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-013-9522-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Double-Blind Parallel Placebo-Controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients with Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention: the MEDCOR Trial

Targeting Matrix Metalloproteinase Activity and Expression for the Treatment of Viral Myocarditis

Sex Differences in Translocator Protein 18 kDa (TSPO) in the Heart: Implications for Imaging Myocardial Inflammation

Blood Outgrowth Endothelial Cells Alter Remodeling of Completely Biological Engineered Grafts Implanted into the Sheep Femoral Artery

Sustained Delivery of Insulin-Like Growth Factor-1/Hepatocyte Growth Factor Stimulates Endogenous Cardiac Repair in the Chronic Infarcted Pig Heart

Relevance of Molecular Mimicry in the Mediation of Infectious Myocarditis